Article info
PDFResearch Article
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
- ↵a elizabeth_buchbinder{at}dfci.harvard.edu
- ↵b jpd4401{at}aol.com
- ↵c gdaniels{at}ucsd.edu
- ↵d Brendan.Curti{at}providence.org
- ↵e SPPatel{at}mdanderson.org
- ↵f sgholtan{at}umn.edu
- ↵g gpmile{at}cox.net
- ↵h mayer.fishman{at}moffitt.org
- ↵i Rene.Gonzalez{at}ucdenver.edu
- ↵j JCLARK{at}lumc.edu
- ↵k richartj{at}slu.edu
- ↵l clao{at}med.umich.edu
- ↵m stykodi{at}fhcrc.org
- ↵n ann_silk{at}dfci.harvard.edu
- ↵o dmcdermo{at}bidmc.harvard.edu
Citation
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
Publication history
- Received October 31, 2018
- Accepted January 31, 2019
- First published February 18, 2019.
Online issue publication
January 08, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© The Author(s).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.